Calendar
October 25, 2024 - Extraordinary general meeting
November 8, 2024 - Interim Report Q3 2024 (7:00am CET)
Investors
Egetis is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment
Share
Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden
Phone: +46 8 679 72 10
E-mail: [email protected]
